Importantly, the frequent molecular dysregulation of KAT6A and KAT6B correlates with survival outcomes of cancers, contributing to the exploration of a wide array of small‐molecule inhibitors against KAT6 catalytic activity. This evidence concerns the gene KAT6A and cancer.